Amalya Sargsyan

Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…

Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

When I first connected with Professor Fedro Peccatori, the line between us was anything but fixed: he was calling from a moving train between Padova to Milan, between obligations. Yet the instability of the connection seemed fitting. His entire career…

From Rome to Milan to ESMO’s presidency — a story of science, courage, and mentorship. I am in Yerevan. Giuseppe Curigliano is in Milan, just back from Asia. “JSMO, CSCO, Korea, Japan, China…” he sighs, then laughs. “Too much travel?”…

It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…

It is often said in medicine that the only true constant in facing life-threatening diseases is change. Nowhere is this more evident than in oncology, where advances in chemotherapy, targeted therapies, immunotherapies, and other novel agents continue to spark hope.…